Treatment of Individuals with Guillain-Barré Syndrome Using a Monoclonal Antibody Therapy Shown to be Safe and Effective
ANX005 (Annexon Biosciences, San Francisco, CA), a monoclonal antibody designed to inhibit the C1q protein complex, significantly improved functional outc…